Bispecific Antibody Characterisation and Analysis

Bispecific antibody characterisation services supporting regulatory considerations for therapeutic development.
Bispecific antibody (BsAb) characterisation and analysis is key to development of this therapeutic class. The activity, efficacy and immunogenicity of a BsAb is influenced by its molecular structure and properties, which by their very nature, can be complex. Characterization programs require multiple analytical approaches to assess all expected properties in line with ICH guidelines.
Bispecific antibodies, comprise of the binding of at least two antigen binding elements within one single bispecific antibody. Many bispecific formats exist and therefore understanding and control of key critical quality attributes (CQAs)) including structure, potency, process-related impurities, chain mis-matching/fragments/homodimers, stability, antigen specificity, affinity and on-off rates and avidity need to be demonstrated in accordance with regulatory guidelines.
Bispecific Antibody Characterisation Expertise
Our scientists offer BsAb characterisation, with a focus on monitoring relevant CQAs. We can help you to demonstrate consistency or comparability of manufactured batches or as release tests for clinical trial materials, stability studies or on-going GMP batch release tests. Our services include:
- Intact molecular weight (MW) and MW distribution (mass spectrometry, SEC-MALS)
- Amino acid sequence and composition (peptide mapping, mass spectrometry, amino acid analysis)
- Glycan profiling (HILIC-FLR-MS)
- Extinction coefficient determination and validation
- Electrophoretic and isoform patterns (cIEF, gel IEF, SDS PAGE, Western Blot, CZE)
- Liquid chromatographic patterns (RP-HPLC, Ion Exchange HPLC, SEC)
- Spectroscopic profile (CD, NMR, FTIR, Fluorescence) for secondary and higher order structure
- Disulphide bridge mapping (Mass spectrometry)
- Terminal amino acid sequencing including K clipping, proline amidation, pyroglutamic acid. (mass spectrometry, CE)
- Evaluation of PTMs including oxidation and deamidation (Mass spectrometry, cIEF)
- Biologic potency assessment
- Product related impurity assessment (RP-HPLC, Ion exchange HPLC, Mass spectrometry)
- Aggregation studies (SEC, DLS, western blot)
- Forced degradation studies
- Quantification of host cell proteins (HCP) -total or individual HCPs and residual DNA
- Physicochemical properties (includes colour, clarity / opalescence, pH, particulates, turbidity, extractable volume, moisture, osmolality)
- Chain mismatching/fragments/homodimers (liquid chromatography-mass spectrometry, size exclusion chromatography-mass spectrometry, CE)
Total Quality Assurance
At Intertek, we apply our experience, industry and regulatory knowledge to design-phase specific analytical development programs, tailored to your BsAb characterisation needs. Bringing quality and safety to life, we offer Total Quality Assurance expertise to help you to meet and exceed quality, safety and regulatory standards.
COVID-19 VACCINE OR THERAPEUTIC TESTING & DEVELOPMENT SUPPORT
IMMEDIATE QUESTION? Ask our experts now
FACTSHEET: COVID-19 Vaccine or Therapeutic Testing & Development Outsourcing
ARTICLE: Repurposing Vaccines for Intranasal Development
WEBINAR: Quality Control Strategy for Vaccine Development
WEBINAR: Repurposing Drugs for Inhaled Delivery
eBOOK: Contingency Outsourcing Solutions
NEW! Discover our Audit Live Tool for direct access to our scheduled audits
EVENT: 2nd Annual Inhaled and Nasal Biologics/DNA Forum - REGISTRATION IS LIVE
VIDEO:EXTRACTABLES/LEACHABLES LAB TOUR - Request access
WORKSHOP: How to Build an Inhaler (RDD 2023)
PRESENTATION:E&L Strategies (3rd Annual Extractables & Leachables Conference)
TALK: Medical Device Extractables & Leachables Studies
TALK: ID and sensitivity issues during E&L studies
ARTICLE: Glycosylation Analytical Approaches for Antibody Therapeutics
APP NOTE: Rapid Determination of Low/Trace Level Benzene in Pharmaceutical Excipients and Finished Products
ARTICLE: Importance of Aligning a Pharma Audit Scope with the Correct Standard
TALK: mRNA Analytics: Capping Efficiency, Sequencing, Poly-A Tail, dsRNA
Intertek Pharmaceutical Services Manchester
P.O. Box 42
Hexagon Tower
Blackley
Manchester, M9 8ZS
United Kingdom
For location use: M9 8GQ
ARTICLES
New Approaches to Bioassay Design
Characterisation of Bispecifics
The Significance and Challenges of Inhaled and Nasal Biologics
Monoclonal Antibody Characterisation - Addressing CQAs
Current Analytical Approaches to Biophysical Characterisation
Biosimilar Characterisation and Immunogenicity
WHITEPAPER DOWNLOADS
GMP Flow Cytometry: Applications, Considerations and Challenges
Liposome Physicochemical Property Analysis
Formulation of Biologics for Inhaled and Nasal Delivery
The Complexities of Antibody Drug Conjugate Characterization
BROCHURES
Download: Intertek Biopharmaceutical Services Brochure
Download: Intertek Pharmaceutical Services